ASCO, page-32

Well that low content is of course worth a response with some real content then. Just to lift the quality of the thread out of the gutter.

Play spot the difference from the two results below. I know it not apples for apples, but it does give some insights....

2018
4 SAEs (including 3 deaths) were reported, none were considered related to NOX66. One Adverse Event (Grade 2 anaemia, NOX66 800mg + carbo AUC4) considered possibly related to NOX66 has been reported.

	Column 1	Column 2	Column 3
1	Completed 6 cycles carbo (AUC4; AUC6)	6	5
2	Evaluable	2 (1SD; 1PD)	3 (2SD; 1PD)
3	Ongoing		3

conclusion NOX66 is well tolerated as a monotherapy and in combination with carboplatin at AUC = 4 or AUC = 6. Efficacy signals from this study warrant further investigation of NOX66 as a chemo-sensitizing agent. Clinical trial information:

https://meetinglibrary.asco.org/record/158635/abstract

RESULTS: 2011
There were no treatment-related deaths. There was only one treatment-related hospitalization and 2 grade 4 toxicities. In the cisplatin arm, there were 3 partial responses, 9 patients (56%) achieved stable disease, 4 (25%) progressed, and the overall best response rate was 19%. In the paclitaxel arm, there was one complete response and 2 partial responses, 8 patients (53%) achieved stable disease, 4 patients (27%) progressed, and the overall best response rate was 20%.
DISCUSSION:

The combination of IV phenoxodiol with cisplatin or paclitaxel was well tolerated in this study. Cisplatin-phenoxodiol was particularly active and warrants further study in patients with platinum-resistant ovarian cancer.
https://www.ncbi.nlm.nih.gov/pubmed/21412168?dopt=Abstract.